



AUG 8 - 2005

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Mr. Jian Vaeches  
Teco Diagnostics  
1268 N. Lakeview Avenue  
Anaheim, CA 92807

Re: k051200  
Trade/Device Name: Hemoglobin A1c Reagent Set, Calibrators, and Controls  
Regulation Number: 21 CFR 864.7470  
Regulation Name: Glycosylated hemoglobin assay  
Regulatory Class: Class II  
Product Code: LCP, JIS, JJX  
Dated: July 15, 2005  
Received: July 15, 2005

Dear Mr. Vaeches:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 –

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,



Carol C. Benson, M.A.  
Acting Director  
Division of Chemistry and Toxicology  
Office of *In Vitro* Diagnostic Device  
Evaluation and Safety  
Center for Devices and  
Radiological Health

Enclosure

**TECO DIAGNOSTICS**



1268 N. Lakeview Ave., Anaheim, CA 92807, U.S.A.  
Phone: (714) 693-7788 Toll Free: 1-800-222-9880  
Fax: (714) 693-3838  
www.tecodiag.com Email: tecodiag@tecodiag.com

**Indications for Use**

510(k) Number (if known): K051200  
~~Unknown at this time~~

Device Name: Hemoglobin A1c Reagent Set ; Calibrators and Controls

**Indications For Use:** Teco Hemoglobin A1c Calibrators are for calibrating results in the quantitative determination of human hemoglobin A1c (HbA<sub>1c</sub>) and Teco Hemoglobin Controls are for the purpose of monitoring accuracy and precision in the quantitative determination of human hemoglobin A1c (HbA<sub>1c</sub>). Teco Hemoglobin A1c Reagent set is for the quantitative determination of Hemoglobin A1c (HbA<sub>1c</sub>) in human blood. The determination of HbA<sub>1c</sub> is most commonly performed for the evaluation of glycemic control in diabetes mellitus. HbA<sub>1c</sub> values provide an indication of glucose levels over the preceding 4-8 weeks. A higher HbA<sub>1c</sub> value indicates poorer glycemic control. For *in vitro* diagnostic use only.

Prescription Use  AND/OR Over-The-Counter Use

(Part 21 CFR 801.109)  
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Division Sign-Off

Page 1 of \_\_\_\_\_

Office of In Vitro Diagnostic Device  
Evaluation and Safety

510: K051200